You are here: Industry Insights > SAGE Therapeutics

News List

Biogen and Sage Therapeutics to co-develop depression and tremor therapies pharmaceutical-technology
December 01, 2020
Biogen and Sage Therapeutics have entered a global collaboration and licence agreement to jointly develop and commercialise depression and tremor therapies, zuranolone (SAGE-217) and SAGE-324, respectively.
Sage Therapeutics' Zulresso becomes first treatment for post-partum depression approved in US firstwordpharma
March 20, 2019
The FDA announced Tuesday that it has cleared Sage Therapeutics' Zulresso (brexanolone) to treat postpartum depression (PPD) in adult women, making it the first drug approved in the US specifically for this indication.
Sage wins OK for depression drug Zulresso. Up next? Major marketing challenges fiercepharma
March 20, 2019
Sage Therapeutics has the first-ever approval for a prescription drug for postpartum depression, thanks to the FDA’s Tuesday nod for Zulresso. But it also has a number of big challenges ahead.
Sage Therapeutics Submits NDA for Intravenous Brexanolone americanpharmaceuticalreview
April 24, 2018
Sage Therapeutics announced the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)
Sage Therapeutics’ Postpartum Depression Drug Heads to the FDA biospace
April 24, 2018
SAGE Therapeutics, located in Cambridge, Massachusetts, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for brexanolone (SAGE-547) to treat postpartum depression (PPD).
Sage Therapeutics Looks to File NDA for Postpartum Depression Treatment Later This Year biospace
January 15, 2018
Cambridge, Mass.-based SAGE Therapeutics closed out 2017 with stellar results for a mid-stage and late-stage trial aimed at treating two kinds of depression.